This is the latest hit for Pfizer’s sickle cell disease portfolio after pulling Oxbryta from the market in 2024.

Pfizer set about evaluating inclacumab in pair of phase 3 studies, dubbed Thrive. The Big Pharma terminated one of those ...

Tonmya – a new under-the-tongue formulation of well-established muscle relaxant cyclobenzaprine HCl – has been cleared to ...

A declining stock price amid steadily rising payouts means Realty Income stock offers an above-average yield of 5.5% at ...

This episode of Pharma Pulse covers a new collaboration to expand access to GLP-1 therapies via LillyDirect, Pfizer’s Phase ...

From clandestine vaccine deals to familial ties with EU-funded ventures, Von der Leyen's leadership has not only eroded ...

Illinois researchers, including some working on vaccines for cancer and rare diseases, worry the federal government turning ...

Less than a year after it was forced to withdraw GBT's sickle cell disease (SCD) therapy Oxbryta from all world markets after ...

Dining under palm trees on a patio at Mar-a-Lago in December, President-elect Donald Trump reassured chief executives at ...

Arvinas Inc. (NASDAQ:ARVN) is one of the best small cap stocks with biggest upside potential. On August 8, Arvinas, in ...

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...

The move would add another barrier for parents who want to vaccinate healthy children ahead of the respiratory virus season.